Large-scale testing (Phase 3)Study completedNCT03696160What this trial is testingThe Late Presenter Treatment Optimisation StudyWho this might be right forHIV/AIDS NEAT ID Foundation 447
Not applicableWithdrawnNCT00023218What this trial is testingEffect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and FibrosisWho this might be right forHIV InfectionsHepatitis C National Institute of Allergy and Infectious Diseases (NIAID)
Testing effectiveness (Phase 2)Study completedNCT01225380What this trial is testingResponse-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis CWho this might be right forChronic Hepatitis C Infection Gilead Sciences 324
Not applicableStudy completedNCT00002205What this trial is testingAn Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment RegimenWho this might be right forHIV Infections Glaxo Wellcome
Large-scale testing (Phase 3)Study completedNCT01370018What this trial is testingTherapy to Elevate CD4 Counts in HIV-1 DiseaseWho this might be right forHIV Disease Institute for Human Genetics and Biochemistry 4
Testing effectiveness (Phase 2)Study completedNCT00002240What this trial is testingStudy of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV DrugsWho this might be right forHIV Infections Bristol-Myers Squibb
Not applicableStudy completedNCT02941874What this trial is testingDetermining of Normal Values and Conformity Assessment of the Dosage of a Plasmatic Marker of the Cellular Captation of Glucose: the IRAP ProteinWho this might be right forInsulin Resistance University Hospital, Grenoble 96
Testing effectiveness (Phase 2)Study completedNCT00046033What this trial is testingComparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 118
Not applicableStudy completedNCT00000859What this trial is testingTrial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3Who this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 1,300
Early research (Phase 1)Study completedNCT01288417What this trial is testingPharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirWho this might be right forHIV InfectionsHCV Infections Radboud University Medical Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT07336446What this trial is testingA Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsWho this might be right forProstate Cancer AstraZeneca 300
Not applicableStudy completedNCT00002387What this trial is testingThe Safety and Effectiveness of Indinavir Sulfate Plus EfavirenzWho this might be right forHIV Infections Merck Sharp & Dohme LLC 80
Post-approval studies (Phase 4)Study completedNCT01472432What this trial is testingDPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 DiabetesWho this might be right forChronic Foot Ulcers University of Campania Luigi Vanvitelli 106
Not applicableStudy completedNCT02191293What this trial is testingLong-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®Who this might be right forHIV Infections Boehringer Ingelheim 228
Not applicableStudy completedNCT00006617What this trial is testingFour-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 25
Testing effectiveness (Phase 2)Study completedNCT02238314What this trial is testingExploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV PatientsWho this might be right forHIV Infections Boehringer Ingelheim 41
Early research (Phase 1)Study completedNCT00001133What this trial is testingSafety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or SaquinavirWho this might be right forHIV Infections National Institute of Allergy and Infectious Diseases (NIAID) 50
Not applicableStudy completedNCT00002417What this trial is testingAmprenavir in Patients With Protease Inhibitor-Related ComplicationsWho this might be right forHIV Infections Glaxo Wellcome
Not applicableApproved For MarketingNCT00097799What this trial is testingTipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 InfectionWho this might be right forHIV Infections Boehringer Ingelheim
Not applicableUnknownNCT01060527What this trial is testingAltered Faecal Protease Activity in Irritable Bowel Syndrome Patients in ChinaWho this might be right forIrritable Bowel Syndrome Xi'an Jiaotong University 60